Company Description
INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients.
It operates through Fertility Clinic Services; INVOcell Device; and Therapeutics segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body.
It also operates fertility clinics, including INVO Centers. In addition, the company develops NY-303, a GPC3 x NKp46 bifunctional antibody that is in Phase i/ii a monotherapy trial for the treatment of hepatocellular carcinoma; and NY-500, an AI-optimized bifunctional antibody.
The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025.
INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.
| Country | United States |
| Founded | 2007 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Steven Shum |
Contact Details
Address: 5582 Broadcast Court Sarasota, Florida 34240 United States | |
| Phone | 978 878 9505 |
| Website | invobioscience.com |
Stock Details
| Ticker Symbol | IVF |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001417926 |
| CUSIP Number | 44984F609 |
| ISIN Number | US44984F8077 |
| Employer ID | 20-4036208 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Steven M. Shum | Chief Executive Officer and Director |
| Andrea Goren | Chief Business Officer |
| Terah Krigsvold | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 24, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 12, 2026 | 424B3 | Prospectus |
| Feb 10, 2026 | EFFECT | Notice of Effectiveness |
| Feb 6, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 2, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jan 30, 2026 | 8-K | Current Report |
| Jan 26, 2026 | 8-K | Current Report |
| Jan 21, 2026 | SCHEDULE 13G/A | Filing |
| Jan 6, 2026 | 8-K | Current Report |